Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ: EXAS) announced that Cologuard is the most cost-effective colorectal cancer screening option for the Alaska Native population, according to a study published in Mayo Clinic Proceedings. The study demonstrates that Cologuard, a non-invasive stool DNA test, produces the highest number of quality-adjusted life years (QALYs) and significantly reduces colorectal cancer incidence compared to colonoscopy and fecal immunochemical test (FIT). With challenges in screening adherence, Cologuard’s home-use capability presents a promising solution for increasing screening rates.

Exact Sciences Corp. (NASDAQ: EXAS) announced the successful acquisition of Ashion Analytics, enhancing its capabilities in precision oncology. This acquisition includes a CLIA-certified lab and advanced genomic testing options, specifically the GEM ExTra® test. The collaboration with The Translational Genomics Research Institute (TGen) aims to improve advanced cancer diagnostics. This strategic move is projected to bolster patient care and extend Exact Sciences' market leadership in cancer treatment.

Exact Sciences Corp. (Nasdaq: EXAS) will release its first quarter 2021 financial results on May 4, 2021, after the U.S. markets close. Following this, a webcast and conference call will be held at 5 p.m. EDT to discuss the results and business developments. The company focuses on cancer screening and diagnostics, leveraging successful products like Cologuard and Oncotype DX. Exact Sciences aims to enhance patient care through innovative solutions and continued investment in its product pipeline.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming virtual investor conferences. The company will hold a fireside chat at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. EST, and at the Barclays Global Healthcare Conference on March 9, 2021, at 9:10 a.m. EST.

Investors can access the webcasts via the investor relations section of Exact Sciences' website. The company continues to focus on cancer screening and diagnostic tests to improve patient care.

Exact Sciences Corp. (Nasdaq: EXAS) reported fourth-quarter 2020 revenue of $466.3 million, with full-year revenue reaching $1.49 billion. Q4 screening revenue grew by 9% to $249.7 million, while COVID-19 testing contributed $99.1 million. However, the company faced a net loss of $436.8 million, or $(2.79) per share, compared to a net income of $78.0 million last year. The acquisition of Base Genomics resulted in a $412.6 million research and development charge. Cash reserves stood at $1.84 billion.

Exact Sciences Corp. (Nasdaq: EXAS) announced its acquisition of Ashion Analytics from The Translational Genomics Research Institute (TGen). Ashion, a CLIA-certified sequencing lab, will enhance Exact's precision oncology portfolio, particularly in minimal residual disease (MRD) testing. The acquisition includes a 10-year research collaboration with TGen and City of Hope to develop advanced MRD testing. This partnership aims to expedite bringing innovative genomic solutions to cancer treatment, leveraging Ashion's expertise and TARDIS technology.

Exact Sciences Corp. (Nasdaq: EXAS) is set to release its fourth quarter 2020 financial results on February 16, 2021, after U.S. market close. Management will host a webcast and conference call at 5 p.m. EST to discuss the financial results and business progress. The company is a leading provider of cancer screening and diagnostic tests, with an emphasis on improving patient care through products like Cologuard and Oncotype DX. For further details, visit their official website.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in February 2021, inviting investors to join via webcast. Key events include:

• BTIG Virtual MedTech Conference on February 18, 2021 at 10:30 a.m. EST
• Citi Healthcare Services Conference on February 24, 2021 at 9:50 a.m. EST
• SVB Leerink Global Healthcare Conference on February 25, 2021 at 1:40 p.m. EST

Investors can access the webcasts on the company's investor relations webpage.

Exact Sciences Corp. (Nasdaq: EXAS) has acquired a worldwide exclusive license for TARDIS technology from TGen, enhancing its position in precision oncology. This innovative approach enables noninvasive detection of minimal residual disease, particularly for patients with small amounts of tumor DNA post-treatment. TARDIS technology demonstrated up to a 100-fold improvement in sensitivity for detecting circulating tumor DNA. This collaboration aims to improve cancer patient outcomes through advanced diagnostics, leveraging Exact Sciences' established expertise with products like Cologuard and Oncotype DX.